Today, the biotechnology sector is witnessing a significant rally, with Compass Pathways (NASDAQ:CMPS) leading the charge. As the company nears the finish line for its Phase 3 clinical trials, a confluence of regulatory tailwinds and political momentum has sent the stock climbing.
The primary driver behind today’s surge is the recent White House Executive Order aimed at accelerating research into psychedelic therapies. For a company like Compass — which was the first to receive FDA “Breakthrough Therapy” designation for psilocybin — this political shift is more than just symbolic. It represents a potential fast-track for their lead candidate, COMP360, as it moves toward a rolling New Drug Application (NDA) submission.
Not Just a Drug, But a “Model of Care”
Compass Pathways Co-Founder George Goldsmith
In a 2022 interview with The Wall Street Transcript, Compass Pathways’ Co-Founder and former Chairman George Goldsmith emphasized that Compass isn’t just selling a pill; they are redesigning how we treat mental illness.
Reflecting on the unique nature of their synthetic psilocybin, Goldsmith noted:
“Our psilocybin, COMP360, is a synthetic pill developed to the highest standards of pharmaceutical development… what’s really different is it’s not just a medicine. It’s a model of care, with people being supported carefully with specially trained therapists who are present during this powerful psychedelic experience.”
This “model of care” is what investors are betting on today. As the health care system looks for solutions to the mental health crisis and treatment-resistant depression, the infrastructure Compass has built — training therapists and establishing specialized treatment centers — is proving to be a competitive moat.
Silencing the “Inner Voice” of Negativity
The excitement surrounding the stock also stems from the clinical data that supports Goldsmith’s original thesis: that this therapy can fundamentally “rewire” a patient’s outlook.
In that same 2022 discussion, Goldsmith described the patient experience in a way that resonated deeply with the medical community:
“What our psilocybin therapy seems to do is it has people see their world in a more positive fashion, disconnecting them from some of that negativity, and also to have less of that inner voice constantly talking things down, but really taking a more positive and a more present view of their life.”
As recent Phase 3 results have confirmed statistically significant improvements in depression scales, Goldsmith’s 2022 description of “disconnecting from negativity” has transitioned from a hopeful hypothesis to a clinical reality.
Looking Ahead
While Goldsmith has moved on from his formal leadership role at the company, passing the CEO torch to commercialization veteran Kabir Nath, his founding vision remains the company’s North Star.
Today’s rally can be viewed as a validation of the vision Goldsmith often described in interviews — a world where, as he famously put it, “no mushrooms are harmed” because the focus is on high-standard pharmaceutical innovation.
Read our 2022 interview with Compass Pathways’ Co-Founder George Goldsmith.
Psilocybin Magic Mushrooms are Now a Publicly Traded Investment Vehicle: COMPASS Pathways (NASDAQ:CMPS)
March 28, 2022
Chad Beynon Sees Upside for Investors in New Expanded Online Gaming Markets: Buy the House, Don't Bet the House
April 15, 2019
DraftKings (NASDAQ:DKNG), Flutter (NYSE:FLUT), Sportradar (NASDAQ:SRAD) and Genius Sports (NYSE:GENI): Why Bet Online When You Can Own the Casino?
November 12, 2025
Why not Natural Gas?
November 20, 2007
